-- Potential First-in-Class Respiratory Combination Vaccine Candidates SCB-1022 (RSV + hMPV) and SCB-1033 (RSV + hMPV + PIV3) Enter the Clinical Trial Stage -- SHANGHAI, June 17, 2025 /PRNewswire/ -- Clover Biopharmaceuticals, Ltd. (Clover; HKEX: 02197), a global commercial-stage...
Read More Details
Finally We wish PressBee provided you with enough information of ( Clover Initiates Phase I Clinical Trial for RSV + hMPV ± PIV3 Respiratory Combination Vaccine Candidates )
Also on site :
- Oil prices up after reports of 3 ships on fire in Gulf of Oman near the strait of Hormuz
- Barbra Streisand, 83, Makes Spicy Confession About This Hollywood Icon
- Legendary Actress, 74, Stuns With 'Ageless Beauty' in Red-Hot Swimsuit